Efficacy and safety of sitagliptin phosphate in type 2 diabetics poorly controlled by antidiabetic drugs
10.3760/cma.j.issn.1671-7368.2012.10.031
- VernacularTitle:磷酸西格列汀对2型糖尿病患者的疗效与安全性观察
- Author:
Jing WANG
;
Yong RUAN
;
Qingying TAN
;
Yun RUAN
- Publication Type:Journal Article
- Keywords:
Dipeptidyl peptidases,antagonists & inhibitors;
Diabetes,type 2
- From:
Chinese Journal of General Practitioners
2012;(10):783-785
- CountryChina
- Language:Chinese
-
Abstract:
A 24-week study was performed to compare the efficacies of before and after dipeptidyl peptidase-4 inhibitor sitagliptin phosphate 100 mg/d in 42 type 2 diabetics who were inadequately controlled with multiple oral antidiabetic drugs for at least 3 months.The treatment group sitagliptin phosphate fasting plasma glucose,2 h postprandial glucose (2 hPPG) and glycated hemoglobulin decreased significantly compared with before treatment [(9.3 ±1.2) to (6.5 ±1.9) mmol/L,(15.2 ±3.1) to (8.1 ±2.1)mmol/L,(8.2 ± 2.1) ％ to (6.7 ± 1.3) ％,all P ＜ 0.01].There was no hypoglycemia,weight gain or other adverse reactions.The short-term sitagliptin phosphate could effectively reduce the blood sugar levels of poorly controlled obese type 2 diabetics.With a low incidence of hypoglycemia and an excellent safety profilc,there was no weight gain.
